EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation

Nathalie Javidi-Sharifi iD, Matthew S Davids iD

Hematological Oncology · 2025

DOI: 10.1002/hon.70064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2025. Verfasst von Nathalie Javidi-Sharifi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: NIH HHS, Wendy Ramsey CLL & Richter's Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), particularly when patients have double‐refractory CLL with progression after both covalent Bruton's tyrosine kinase inhibitors (BTKi) and venetoclax, as well as Richter Transformation (RT) remain significant clinical challenges. These patients face poor outcomes, necessitating novel treatment approaches. Recently approved therapies such as a non‐covalent BTKi and CAR‐T cells provide new options, while BTK degraders and bispecific antibodies are showing early promise in clinical trials. For RT, venetoclax‐based chemoimmunotherapy combinations may increase rates of complete response, but remain inadequate for many, highlighting the need for novel therapeutic approaches. This review synthesizes recent advancements in R/R CLL and RT treatment, discussing approved therapies, investigational agents, and combination strategies aimed at improving outcomes in these high‐risk populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellHumansDisease ManagementDrug Resistance, NeoplasmProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsRecurrenceAgammaglobulinaemia Tyrosine Kinase

Stichwörter der Autor:innen

BTK inhibitorsCAR‐T therapyRichter's Transformation (RT)bispecific antibodieschronic lymphocytic leukemia (CLL)double‐refractory

Substanzen

Protein Kinase InhibitorsAgammaglobulinaemia Tyrosine Kinase

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

ORCID-Profile: Nathalie Javidi-Sharifi, Matthew S Davids

Förderung

  • NIH HHS
  • Wendy Ramsey CLL & Richter's Research Fund

Zitieren

APA

Javidi-Sharifi, N., & Davids, M. S. (2025). Advances in the Management of Relapsed/Refractory CLL and Richter Transformation. Hematological Oncology. https://doi.org/10.1002/hon.70064

Vancouver

Javidi-Sharifi N, Davids MS. Advances in the Management of Relapsed/Refractory CLL and Richter Transformation. Hematological Oncology. 2025. doi:10.1002/hon.70064

BibTeX
@article{JavidiSharifi2025,
  author = {Javidi-Sharifi, Nathalie and Davids, Matthew S},
  title = {Advances in the Management of Relapsed/Refractory CLL and Richter Transformation},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70064}
}
Kostenlos starten →